

Edgar Filing: TRANSGENOMIC INC - Form 8-K

TRANSGENOMIC INC

Form 8-K

July 15, 2005

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JULY 13, 2005

TRANSGENOMIC, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State of Formation)

000-30975
(Commission File Number)

911789357
(IRS Employer Identification Number)

12325 Emmet Street
Omaha, NE
(Address of principal executive offices)

68164
(Zip Code)

(402) 452-5400
(Registrants' telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c))

=====

ITEM 8.01 OTHER EVENTS.

On July 13, 2005, the Company issued a press release detailing comments made at its annual meeting of shareholders, including projections of neutral to positive operating cash flow by year end, and BioSystems revenue growth

Edgar Filing: TRANSGENOMIC INC - Form 8-K

approaching 20% year over year. A copy of the press release is filed herewith as Item 9.01 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibits

(99) Press Release, dated July 13, 2005, detailing comments made at its annual meeting of shareholders, including projections of neutral to positive operating cash flow by year end, and BioSystems revenue growth approaching 20% year over year.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRANSGENOMIC, INC.

By /s/ Mitchell L. Murphy

Mitchell L. Murphy
VP, Secretary & Treasurer

July 15, 2005

3